ALNY News and Press, Alnylam Pharmaceuticals Inc. From 02/11/22

HQL pays quarterly dividends. Even during the pandemic, its performance has been better than its peers. Current prices look attractive. For further details see: Tekla Life Sciences Investors: Buy For Steady, Quarterly Dividend

Alnylam Pharmaceuticals (ALNY +3.0%) is trading higher after the company reported better than expected revenue for Q4 2021, while the bottom line missed expectations amid a rise in the cost base. Quarterly revenue climbed ~58% YoY to $258.5M expanding the annual revenue by ~71% YoY to $844.3M...

Alnylam Pharmaceuticals, Inc. (ALNY) Q4 2021 Earnings Conference Call February 10, 2022 8:30 AM ET Company Participants Christine Lindenboom – Senior Vice President of Investor Relations and Corporate Communications Yvonne Greenstreet – Chief Executive Officer Tolga Tanguler &#x...

Alnylam Pharmaceuticals press release (NASDAQ:ALNY): Q4 Non-GAAP EPS of -$1.69 misses by $0.43. Revenue of $258.54M (+58.1% Y/Y) beats by $24.92M. Shares +0.2% PM. Provides 2022 Combined Net Product Revenue Guidance of $900 Million to $1 Billion, in Addition to Collaboration & Royalty Rev...

− Achieved Fourth Quarter and Full Year 2021 Global Net Product Revenues of $199 Million and $662 Million, Respectively, Representing 83% Annual Growth Compared to 2020 – − Reported Positive 18-Month Results from HELIOS-A Phase 3 Study of Vutrisiran in...

Alnylam Pharmaceuticals (NASDAQ:ALNY) is scheduled to announce Q4 earnings results on Thursday, February 10th, before market open. The consensus EPS Estimate is -$1.26 (+21.3% Y/Y) and the consensus Revenue Estimate is $233.62M (+42.8% Y/Y). Over the last 2 years, ALNY has beaten EPS estimate...

Investing in the biotech industry is an art, not a science. While the potential for gains from groundbreaking therapies exists, the majority fail. By utilizing statistics, careful selection, and net present value calculations, it is quite easy to find a basket that fulfills your p...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the 11 th Annual SVB Leerink Global Healthcare Conference, being held virtually, on Thursday, February 17, 2022 at 10:00 am ET....

Gainers: Alnylam Pharmaceuticals (NASDAQ:ALNY) +12%. ImmunityBio  (NASDAQ:IBRX) +6%. Ortho Clinical Diagnostics Holdings  (NASDAQ:OCDX) +5%. Qorvo (NASDAQ:QRVO) +5%. Vanda Pharmaceuticals  (NASDAQ:VNDA) +4%. Losers: COMPASS Pathways P(NASDAQ:CMPS) +-5%. GreenSky (NASD...

Design Therapeutics (NASDAQ:DSGN) announced the appointment of Jae Kim, M.D., as the company’s new Chief Medical Officer. Before joining Design (DSGN), Dr. Kim served as the chief medical officer at Avidity Biosciences, leading the advancement of its pipeline, including the start of a ...